Search

everythinglearnresearchcommunity

for

Search:↓

Vinblastine and its metabolites may cause nausea and hair loss by binding to specific receptors and could lead to better chemotherapy drugs with fewer side effects.

5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Chemoprevention can significantly lower cancer risks and needs more research and collaboration.

Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.

The treatment combination is effective and generally safe for lung cancer.

Deucravacitinib helped a man regrow hair and improve psoriasis.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.

Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.

Tofacitinib might be used to treat hair loss.

Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

The rash resolved after stopping ponatinib.

Verteporfin reduces growth and stem cell traits in rat hair follicle cells by blocking the Hippo pathway.

Indinavir, especially with vitamin A, may cause bone changes, but switching to nelfinavir can reduce these effects.

Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Upadacitinib may cause hair loss.